# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The decrease year-over-year was primarily driven by lower revenues from GSK following the restructuring of the partnership in J...
Under the terms of the agreements, CureVac and GSK will receive in aggregate a payment of $740 million as well as single-digit ...
BioNTech beat Q2 estimates with higher COVID vaccine revenue and reaffirmed 2025 guidance.
UBS analyst Eliana Merle downgrades CureVac (NASDAQ:CVAC) from Buy to Neutral and lowers the price target from $12 to $5.5.
Jefferies analyst Roger Song downgrades CureVac (NASDAQ:CVAC) from Buy to Hold and lowers the price target from $7 to $5.